GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (STU:BT1) » Definitions » Growth Rank

Biosenic (STU:BT1) Growth Rank : 0 (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biosenic Growth Rank?

Biosenic has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Biosenic Growth Rank Related Terms

Thank you for viewing the detailed overview of Biosenic's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosenic (STU:BT1) Business Description

Traded in Other Exchanges
Address
Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, Gosselies, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (STU:BT1) Headlines

No Headlines